6C51.0,1,Z F63.8
Conditions
Interventions
Group 1: On the study website interested people fill in a questionnaire measuring problematic internet usage. After a short feedback regarding their usage behaviour, they can create their own user acc
Sponsors
LWL-Universitätsklinikum Bochum, Klinik für Psychosomatische Medizin und Psychotherapie
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Constant access to the internet via webcam and an email address. 2. Legal age or at least 16 years old with the informed consent of one parent to participate at the study. 3. Sufficient knowledge of the German language. 4. Informed consent to dissolve the pseudonymization in case of emergency (i.e. concrete suicidal tendency of the attendee).
Exclusion criteria
Exclusion criteria: 1.) Acute psychotic episode 2.) Acute suicidal tendency or self-endangerment 3.) Clear mental retardation 4.) Acute substance-use disorder 5.) Under 16 years old, or no legal age and without parental informed consent 6.) Deficient knowledge of the German language 7.) Inconstant/No access to the internet via webcam. No email address. 8.) Comorbid somatic disease with endocrinological medication causing impulsive behaviours (e.g. Morbus Parkinson with dopaminergic medication) 9.) recent psychiatric or psychotherapeutic treatment focusing primary on Internet addiction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is a reduction in PIU severity measured by the Skala zum Onlinesuchtverhalten bei Erwachsenen (OSV-S, Wölfling et al. 2010). The outcomes will be measured at five (or six, respectively) assessments: before starting the intervention (t0), after 2 weeks of intervention (t1), after completion of the intervention (t2) and 4-6 weeks follow-up (t3a). The waiting group additionally fulfill the questionnaires at a second follow-up (t3b). Members of both groups participate at a second follow-up assessment after 6 months (t4). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes of the study are: 2. An increase of the motivation to change the problematic behaviour and potentially undergo a therapy measured by the Stages of Change Readiness and Treatment Eagerness Scale (iSOCRATES-D, Miller & Tonigan, 1996). 3. An enhanced quality of life measured both by the Single-Item Skala to assess general life satisfaction (L-1, Beierlein, Kovaleva & Lázló, 2014) and the EQ5D (EuroQol Group, 1990) to assess health related quality of life. 4. A reduction of depression and anxiety severity measured by the PHQ-9 and the GAD-7 of the general health questionnaire for patients (PHQ-D, Löwe et al., 2002). 5. An enhancement of social, mental and global functioning measured by the Global Assessment of Functioning (GAF, American Psychiatric Association, 1989). 6. Explorative analyses to indicate potential risk factors in the development and maintainance of PIU. 7. Rate of mediation in analogue treatment. The outcomes will be measured at five (or six, respectively) assessments: before starting the intervention (t0), after 2 weeks of intervention (t1), after completion of the intervention (t2) and 4-6 weeks follow-up (t3a). The waiting group additionally fulfill the questionnaires at a second follow-up (t3b). Members of both groups participate at a second follow-up assessment after 6 months (t4). | — |
Countries
Germany
Contacts
Public ContactJan Dieris-Hirche
LWL-Universitätsklinikum Bochum, Klinik für Psychosomatische Medizin und Psychotherapie
Outcome results
None listed